Buchumschlag

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bérard, Emilie (VerfasserIn) , Röllig, Christoph (VerfasserIn) , Bertoli, Sarah (VerfasserIn) , Pigneux, Arnaud (VerfasserIn) , Tavitian, Suzanne (VerfasserIn) , Kramer, Michael (VerfasserIn) , Serve, Hubert (VerfasserIn) , Bornhäuser, Martin (VerfasserIn) , Platzbecker, Uwe (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Baldus, Claudia D. (VerfasserIn) , Martínez-Cuadrón, David (VerfasserIn) , Serrano, Josefina (VerfasserIn) , Martínez-Sánchez, Pilar (VerfasserIn) , Arbolí, Eduardo Rodríguez (VerfasserIn) , Gil, Cristina (VerfasserIn) , Bergua, Juan (VerfasserIn) , Bernal, Teresa (VerfasserIn) , de la Fuente Burguera, Adolfo (VerfasserIn) , Delabesse, Eric (VerfasserIn) , Bidet, Audrey (VerfasserIn) , Dumas, Pierre-Yves (VerfasserIn) , Montesinos, Pau (VerfasserIn) , Recher, Christian (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 July 2022
In: Blood cancer journal
Year: 2022, Jahrgang: 12, Heft: 7, Pages: 1-8
ISSN:2044-5385
DOI:10.1038/s41408-022-00700-x
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41408-022-00700-x
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41408-022-00700-x
Volltext
Verfasserangaben:Emilie Bérard, Christoph Röllig, Sarah Bertoli, Arnaud Pigneux, Suzanne Tavitian, Michael Kramer, Hubert Serve, Martin Bornhäuser, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, David Martínez-Cuadrón, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez Arbolí, Cristina Gil, Juan Bergua, Teresa Bernal, Adolfo de la Fuente Burguera, Eric Delabesse, Audrey Bidet, Pierre-Yves Dumas, Pau Montesinos and Christian Récher
Beschreibung
Zusammenfassung:In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML patients aged 70 years or older treated with intensive chemotherapy were used to develop a prognostic scoring system. The median follow-up was 50.8 months. In the training set of 636 patients, age, performance status, secondary AML, leukocytosis, and cytogenetics, as well as NPM1 mutations (without FLT3-ITD), were all significantly associated with overall survival, albeit not to the same degree. These factors were used to develop a score that predicts long-term overall survival. Three risk-groups were identified: a lower, intermediate and higher-risk score with predicted 5-year overall survival (OS) probabilities of ≥12% (n = 283, 51%; median OS = 18 months), 3-12% (n = 226, 41%; median OS = 9 months) and <3% (n = 47, 8%; median OS = 3 months), respectively. This scoring system was also significantly associated with complete remission, early death and relapse-free survival; performed similarly in the external validation cohort (n = 563) and showed a lower false-positive rate than previously published scores. The European Scoring System ≥70, easy for routine calculation, predicts long-term survival in older AML patients considered for intensive chemotherapy.
Beschreibung:Gesehen am 21.02.2023
Beschreibung:Online Resource
ISSN:2044-5385
DOI:10.1038/s41408-022-00700-x

Ähnliche Einträge